GLP-1 & weight-loss clinical trials in Illinois
15 GLP-1 or weight-loss trials are recruiting in Illinois as of July 14, 2026, with sites in Chicago, Gillespie, Gurnee, Schaumburg, Skokie and more. Many studies reimburse time and travel — the amount is set by each study and confirmed when you contact the team.
- A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
Phase 2 · ~1481 participants · NCT06143956
Studied intervention: Tirzepatide
Illinois sites: Chicago, Skokie
- Randomized Control Trial of Sleeve Gastrectomy With Tirzepatide in Maximizing Weight Loss
EARLY_Phase 1 · ~42 participants · NCT06734273
Studied intervention: Mounjaro
Illinois site: Chicago
- A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
Phase 4 · ~200 participants · NCT06864026
Studied intervention: Tirzepatide
Illinois sites: Chicago, Schaumburg, Skokie, Willowbrook
- A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
Phase 2 · ~465 participants · NCT06717698
Studied intervention: Semaglutide
Illinois site: Skokie
- A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity
Phase 2 · ~230 participants · NCT07639021
Studied intervention: Semaglutide, Semaglutide placebo
Illinois site: Chicago
- A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
Phase 3 · ~800 participants · NCT07153471
Studied intervention: Orforglipron
Illinois site: Chicago
- A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
Phase 3 · ~125 participants · NCT06672549
Studied intervention: Orforglipron
Illinois site: Chicago
- Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
Phase 3 · ~1200 participants · NCT07284979
Studied intervention: Semaglutide
Illinois sites: Chicago, Skokie
- People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists
Interventional · ~100 participants · NCT07207148
Studied intervention: GLP-1
Illinois site: Chicago
- A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
Phase 3 · ~2500 participants · NCT07564414
Studied intervention: Semaglutide
Illinois sites: Chicago, Gillespie, Gurnee, Skokie
- A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
Phase 3 · ~150 participants · NCT06672939
Studied intervention: Orforglipron
Illinois site: Chicago
- A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
Phase 3 · ~300 participants · NCT06439277
Studied intervention: Tirzepatide
Illinois site: Chicago
- Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Phase 3 · ~290 participants · NCT06937099
Studied intervention: Tirzepatide
Illinois site: Chicago
- Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
Phase 3 · ~200 participants · NCT06499857
Studied intervention: Semaglutide
Illinois site: Chicago
- Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
Phase 3 · ~350 participants · NCT06937086
Studied intervention: Tirzepatide
Illinois site: Chicago
What joining a GLP-1 trial in Illinois actually involves
Every study above is registered on ClinicalTrials.gov, the US National Library of Medicine's public registry, and each link goes straight to that record — the one place the eligibility criteria, the schedule of visits and the contact details are kept current. A recruiting listing means the study is actively enrolling; it does not mean you are eligible until the study team screens you.
- Reimbursement is not the same as payment. Many studies cover time and travel, but the amount is set per study and confirmed by the team — treat any specific figure you see elsewhere as unverified until they tell you.
- You may receive a placebo. Most of these are randomized, so joining is not a guaranteed route to the active drug. That is worth weighing if your goal is treatment rather than contributing to the evidence.
- Trial participation is free to join and separate from a prescription. If your aim is to start a GLP-1 now, compare the cash-pay routes instead — trials are a different path with a different purpose.
Source: ClinicalTrials.gov (US National Library of Medicine), public-domain data, snapshot July 14, 2026. This is not medical advice or a recruitment service — confirm status, eligibility, and compensation on each linked ClinicalTrials.gov record and discuss any trial with your clinician.